Amiodarone-induced hepatic injury

Qiufen Xie,Qian Xiang,Ying Zhou,Yimin Cui
DOI: https://doi.org/10.3760/cma.j.issn.1008-5734.2014.06.010
2014-01-01
Abstract:Amiodarone,one of Class Ⅲ antiarrhythmic drugs,may lead to hepatic injury,the incidence of which is about 14% to 82% . Clinical manifestations differ widely from asymptomatic elevated liver enzymes to fulminant hepatic failure and even death. Histopathological findings are similar to those of alcoholic liver disease and characterized by lysosomes phospholipidosis and granular cells. Pathogenesis includes toxicity of amiodarone and its major metabolite,immunological mechanisms,and genetic factors. Intravenous AIHI is mainly related to the effect of cosolvent,polysorbate 80. Men,heart failure and plasma concentration >2.5 mg/ L may be risk factors. Indications to use amiodarone should be strictly controlled and patients' physical conditions should be considered for choosing methods of administration. Monitoring closely is needed for liver function and/ or blood concentration during treatment. When liver function is abnormal, weigh the benefits and risks of treatment carefully,and decide whether dosage reduction or withdrawal of the drug is necessary.
What problem does this paper attempt to address?